Abuse liability of flunitrazepam

Journal of Clinical Psychopharmacology

Volumn 17, Issue 3 SUPPL. 2, 1997, Pages

  Woods, James H ^a   Winger, Gail ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; FLUNITRAZEPAM;

DEPENDENT PERSONALITY DISORDER; DOSE RESPONSE; DRUG ABUSE; DRUG EFFICACY; DRUG OVERDOSE; DRUG STRUCTURE; INSOMNIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; WITHDRAWAL SYNDROME;

EID: 0030938655     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199706001-00001     Document Type: Review

References (232)

1. World Health Organization (WHO) Expert Committee on Drug Dependence. Twenty-ninth report. WHO Technical Report Series, No. 856. Geneva: World Health Organization, 1995.
2. World Health Organization. Convention on psychotropic substances, publication E/CONF.58/6. New York: United Nations, 1971.
3. National Institute on Drug Abuse. Epidemiologic trends in drug abuse, volume I: highlights and executive summary. NIH Publication No. 96-4128. Rockville, MD: National Institutes of Health, 1996.
4. Friend T. Date-rape drug. USA Today, June 20, 1996.
5. Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10: 237-43.
6. Rush CR, Higgins ST, Bickel WK, Hughes JR. Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. Neurosci Biobehav Rev 1993;17:277-85.
7. Jonas JM. Idiosyncratic side effects of short half-life benzodiazepine hypnotics: fact or fancy. Hum Psychopharmacol 1992;7: 205-16.
8. Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53:19-33.
9. King DJ. Benzodiazepines, amnesia and sedation: theoretical and clinical issues and controversies. Hum Psychopharmacol 1992;7: 79-87.
10. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987;39:251-419.
11. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992;44:151-347.
12. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology 1995;118:107-15.
13. Woods JH, Katz JL, Winger G. Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1777-91.
14. Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet 1989;16:1-26.
15. Farré M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991;86:1601-6.
16. Greenblatt DJ. Clinical implications of pharmacokinetic differences among benzodiazepines. Actual Med Int Psychiatr 1985;2: 8-12.
17. Jochemsen R, van Boxtel CJ, Hermans J, Breimer DD. Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther 1983;34:42-7.
18. Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, Paul SM. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology 1987;93:72-6.
19. Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 1988;245:816-22.
20. Lader M. Anxiolytic drugs: dependence, addiction and abuse. Eur Neuropsychopharmacol 1994;4:85-91.
21. Keup W. Flunitrazepam (Rohypnol) erreicht spitzenplatz als drogen-ersatzmittel. Sucht 1995;41:362-6.
22. Bond A, Seijas D, Dawling S, Lader M. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994;89: 821-30.
23. McGowan WAW, Dundee JW, Clarke RSJ, Howard PJ. Comparison of the subjective effects and plasma concentrations following oral and I.M. administration of flunitrazepam in patients. Br J Anaesth 1980;52:447-51.
24. Kangas L, Kanto J, Pakkanen A. A pharmacokinetic and pharmacodynamic study of flunitrazepam. Int J Clin Pharmacol 1982;20: 585-8.
25. Grahnén A, Wennerlund P, Dahlstrom B, Eckernäs SA. Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam. Br J Clin Pharmacol 1991;31:89-92.
26. Jochemsen R, Breimer DD. Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles. Curr Med Res Opin 1984;8:60-79.
27. Amrein R, Cano JP, Hartmann D, Ziegler WH, Dubuis R. Clinical and psychometric effects of flunitrazepam observed during the day in relation to pharmacokinetic data. In: Priest RG, Pletscher A, Ward J, eds. Sleep research. Proceedings of the Northern European Symposium on Sleep Research, Basle. Baltimore: University Park Press, 1979:83-98.
28. Wickstrøm E, Amrein R, Haefelfinger P, Hartmann D. Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. Eur J Clin Pharmacol 1980;17:189-96.
29. Braestrup C, Squires RF. Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol 1978;48: 263-70.
30. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines: correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 1991;257:472-8.
31. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
32. Ingum J, Pettersen G, Sager G, Mørland J. Relationship between unbound plasma concentrations and various psychomotor and subjective effects after intakes of diazepam and flunitrazepam. Int Clin Psychopharmacol 1994;9:115-21.
33. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez CM, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:654-9.
34. Cappell H, Busto U, Kay G, Naranjo CA, Sellers EM, Sanchez CM. Drug deprivation and reinforcement by diazepam in a dependent population. Psychopharmacology 1987;91:154-60.
35. de Wit H, Pierri J, Johanson CE. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers. Pharmacol Biochem Behav 1989;33:205-13.
36. Roache JD, Stanley MA, Creson DL, Meisch RA, Shah NN. Diazepam reinforcement in anxious patients. Exp Clin Psychopharmacol 1996;4:308-14.
37. Roehrs T, Pedrosi B, Rosenthal L, Roth T. Hypnotic self administration and dose escalation. Psychopharmacology 1996;127: 150-4.
38. Yanagita T, Miyasato K, Kiyohara H. Drug dependence potential test of flunitrazepam (Ro 5-4200) tested in rhesus monkeys. Cent Inst Exp Anim Preclin Rep 1977;3:1-7.
39. Yanagita T, Kato S, Miyasato K. Dependence potential of flunitrazepam tested in rhesus monkeys. Cent Inst Exp Anim Preclin Rep 1981;7:37-42.
40. Yanagita T. A comparison of the dependence potentials of various benzodiazepines assessed in rhesus monkeys. WHO working paper for the Fifth Review of Psychoactive Substances for International Control (November 16-20, 1981, Geneva), MNH/R5/81.10. Geneva: World Health Organization, 1981.
41. Winger G, Woods JH, Patrick GA, Powell LJ, Harris LS, Nader MA, Woolverton WL. Progress report from the testing program for stimulant and depressant drugs (1991). Nat Inst Drug Abuse Res Monogr Ser 1992;119:625-39.
42. Nader MA, Winger G, Woods JH, Woolverton WL. Discriminative and reinforcing effects of brotizolam in rhesus monkeys. Psychopharmacology 1991;103:166-71.
43. Shannon HE, Herling S. Discriminative stimulus effects of diazepam in rats: evidence for a maximal effect. J Pharmacol Exp Ther 1983;227:160-6.
44. Garcha HS, Rose IC, Stolerman IP. Midazolam cue in rats: generalization tests with anxiolytic and other drugs. Psychopharmacology 1985;87:233-7.
45. Woudenberg F, Slangen JL. Discriminative stimulus properties of midazolam: comparison with other benzodiazepines. Psychopharmacology 1989;97:466-70.
46. Young R, Glennon RA. Stimulus properties of benzodiazepines: correlations with binding affinities, therapeutic potency and structure activity relationships (SAR). Psychopharmacology 1987; 93:529-33.
47. Terán MT, Farré M, Lamas X, Ugena B, Cami J. Subjective and psychomotor effects of flunitrazepam in healthy volunteers. Nat Inst Drug Abuse Res Monogr Ser 1993;132:348.
48. Farré M, Terán MT, Cami J. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology 1996;125:1-12.
49. Ferreira L, Oliveira MJ, Hindmarch I. Benzodiazepine misuse in poly-drug users. Int Congr Symp Ser 1983;74:105-9.
50. Barnas C, Rossmann M, Roessler H, Riemer Y, Fleischhacker WW. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992;12:397-402.
51. Ladewig DR, Hersberger K, Borner S. Benzodiazepine in der drogenszene. Schweiz Apoth Ztg 1995;133:319-22.
52. Darke SG, Ross JE, Hall WD. Benzodiazepine use among injecting heroin users. Med J Aust 1995;162:645-7.
53. Keup W. Flunitrazepam (Rohypnol) - füehrend beim missbrauch unter den benzodiazepin-derivaten. Sucht 1992;38:3-6.
54. Farré M, Terán MT, Roset N, Menoyo E, Torrens M, Cami J. Abuse liability of flunitrazepam and triazolam in methadone-maintenance patients [abstract]. In: Abstracts, College on Problems of Drug Dependence 58th Annual Scientific Meeting, 1996:39.
55. Hollister L. Clinical pharmacology of psychotherapeutic drugs, 2nd ed. New York: Churchill Livingstone, 1983.
56. Martin WR, Sloan JW, Wala E. Precipitated abstinence in orally dosed benzodiazepine-dependent dogs. J Pharmacol Exp Ther 1990;255:744-55.
57. Sloan JW, Martin WR, Wala EP. A comparison of the physical dependence inducing properties of flunitrazepam and diazepam. Pharmacol Biochem Behav 1991;39:395-405.
58. Martin JR, Moreau JL, Jenck F. Precipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam. Psychopharmacology (Berl) 1995;118:273-9.
59. Xin J, Wala EP, Sloan JW. Flunitrazepam and nordiazepam slowly released from silastic capsules induce physical dependence in rat. Drug Alcohol Depend 1995;391:63-7.
60. Himmelsbach CK. The effects of certain chemical changes on the addiction characteristics of drugs of the morphine, codeine series. J Pharmacol Exp Ther 1941;71:41-8.
61. van der Laan JW, van't Land CJ. Withdrawal hyperactivity after chronic treatment with lorazepam: cross-suppression studies with other benzodiazepines. Psychopharmacology 1990; 101:226.
62. Maldonado R, Micó JA, Valverde O, Saavedra MC, Leonsegui I, Gibert-Rahola J. Influence of different benzodiazepines on the experimental morphine abstinence syndrome. Psychopharmacology 1991;105:197-203.
63. Valverde O, Micó JA, Maldonado R, Gibert-Rahola J. Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. Drug Alcohol Depend 1992;30:293-300.
64. Valverde O, Maldonado R, Mico JA, Gibert-Rahola J. Study of the mechanisms involved in behavioral changes induced by flunitrazepam in morphine withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:973-91.
65. Castellano C, Filibeck U, Pavone F. Naltrexone-reversible effects of flunitrazepam on locomotor activity and passive avoidance behaviour in mice. Eur J Pharmacol 1984;104:111-6.
66. Kales A, Soldatos CR, Bixler EO, Kales JD. Rebound insomnia and rebound anxiety: a review. Pharmacology 1983;26:121-37.
67. Hindmarch I, Parrott AC, Arenillas L. A repeated dose comparison of dichloralphenazone, flunitrazepam and amylobarbitone sodium on some aspects of sleep and early morning behaviour in normal subjects. Br J Clin Pharmacol 1977;4:229-33.
68. Bixler EO, Kales A, Soldatos CR, Kales JD. Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations. J Clin Pharmacol 1977;17:569-78.
69. Scharf MB, Bixler EO, Kales A, Soldatos C. Long-term sleep laboratory evaluation of flunitrazepam. Pharmacology 1979;19: 173-81.
70. Guilleminault C, Seidel LW, Chernik DA, Dement WC. Objective long-term nocturnal and daytime evaluation of flunitrazepam. In: Koella WP, ed. Sleep 1982. Physiology, pharmacology, sleep factors, memory, sleep deprivation, hypnotics. 6th European Congress on Sleep Research, Zurich, March 23-26, 1982. New York: Karger, 1983:430-2.
71. Okudaira N, Suenaga K, Nishihara K, Iguchi Y, Torii S. Objective daytime sleepiness, night sleep and benzodiazepines: evaluation of the effects of short-, intermediate- and long-acting drugs on sleep. Jpn J Psychiatry Neurol 1988;42:143-4.
72. Frattola L, Maggioni M, Cesana B, Priore P. Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac inpatients. Drugs Exp Clin Res 1990;16:371-6.
73. Guazzelli M, Ciapparelli A, Balsamo EL, Gemignani A, Sarteschi P. Terapia dell'insonnia correlata con i disturbi depressivi: studio in doppio cieco sugli effetti della somministrazione e della sospensione di zolpidem versus flunitrazepam in pazienti depressi insonni. Minerva Psichiatr 1993;34:193-203.
74. Hajak G, Clarenbach P, Fischer W, Haase W, Rüther E. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994;9:251-61.
75. Hartelius H, Larsson AK, Lepp M, Malm U, Arvidsson A, Dahlström H. A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects. Acta Psychiatr Scand 1978;58:1-15.
76. Vescovi PP, Gerra G, Ippolito L, Caccavai R, Maestri D, Passeri M. Nicotinic acid effectiveness in the treatment of benzodiazepine withdrawal. Curr Ther Res Clin Exp 1987;41:1017-21.
77. Duka T, Ackenheil M, Noderer J, Doenicke A, Dorow R. Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788. Psychopharmacology (Berl) 1986;90:351-7.
78. Noderer J, Duka T, Dorow R. Benzodiazepin-antagonisierung mit Ro 15-1788: psychometrische, hormonelle und biophysikalische parameter. Anaesthesist 1988;37:535-42.
79. Fialip J, Aumaitre O, Eschalier A, Maradeix B, Dordain G, Lavarene J. Benzodiazepine withdrawal seizures: analysis of 48 case reports. Clin Neuropharmacol 1987;10:538-44.
80. Zenut-Leaud M, Deffond D, Cros E, Fialip J, Dordain G, Lavarenne J. En cours de traitement ou à l'arrêt... les accidents convulsifs liés aux médicaments: a propos de 70 observations. Therapie 1994;49:439-42.
81. Martinez-Cano H, Vela-Bueno A, de Iceta M, Pomalima R, Martinez-Gras I. Benzodiazepine withdrawal syndrome seizures. Pharmacopsychiatry 1995;28:257-62.
82. Guthrie SK. The treatment of alcohol withdrawal. Pharmacotherapy 1990;9:131-43.
83. Pycha R, Miller C, Barnas C, Hummer M, Stuppäck C, Whitworth A, Fleischhacker WW. Intravenous flunitrazepam in the treatment of alcohol withdrawal delirium. Alcohol Clin Exp Res 1993; 17:753-7.
84. Bond AJ, Lader MH. Residual effects of flunitrazepam. Br J Clin Pharmacol 1975;2:143-50.
85. Lader M, Melhuish A, Harris P. Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam. Eur J Clin Pharmacol 1982;23:135-40.
86. Hindmarch I. A repeated dose comparison of three benzodiazepine derivatives (nitrazepam, flurazepam and flunitrazepam) on subjective appraisals of sleep and measures of psychomotor performance the morning following night-time medication. Acta Psychiatr Scand 1977;56:373-81.
87. Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gerne M, Strauch I, Lehmann D, Borbély AA. Day-time residual effects and motor activity after three benzodiazepine hypnotics. Arzneimittelforschung 1982;32:461-5.
88. Borland RG, Nicholson AN, Spencer M, Stone BM. Hypnotics with single and multi-compartment model kinetics: sleep and performance studies in man. Br J Clin Pharmacol 1982;13:272P-3P.
89. Perianu M, Berthaux P, Le Go A. Evaluation of night sleep and performance in the morning: comparison of two benzodiazepines in geriatric patients. In: Koella WP, ed. Sleep 1982. Physiology, pharmacology, sleep factors, memory, sleep deprivation, hypnotics. 6th European Congress on Sleep Research, Zurich, March 23-26, 1982. New York: Karger, 1983:409-12.
90. Borbély AA, Fellmann I, Gerne M, Lehmann D, Loepfe M, Mattmann P, Strauch I. Benzodiazepine hypnotics: prolonged residual effects after a single dose. Experientia 1982;38:752.
91. Ott H. Are electroencephalographic and psychomotor measures sensitive in detecting residual sequelae of benzodiazepine hypnotics? Psychopharmacology Suppl 1984;1:133-51.
92. Patat A, Foulhoux P, Klein MJ. Etude des effets résiduels sur l'équilibre de trois hypnotiques (loprazolam, flunitrazépam, triazolam) appréciés par l'analyse spectrale des oscillations posturales. Therapie 1986;41:443-7.
93. Cluydts R, De Roeck J, Schotte C, Horrix M. Comparative study on the residual daytime effects of flunitrazepam, triazolam and placebo in healthy volunteers. Acta Ther 1986;12:205-18.
94. Salonen M, Aaltonen L, Aantaa E, Kanto J. Saccadic eye movements in determination of the residual effects of the benzodiazepines. Int J Clin Pharmacol Ther Toxicol 1986;24:227-31.
95. Okudaira N, Suenaga K, Nishihara K, Koike H, Iguchi Y, Toni S. Daytime sleepiness and performance: evaluation of the effects of short-, intermediate- and long-acting benzodiazepines on sleep. Jpn J Psychiatry Neurol 1988;42:704.
96. Hindmarch I. Residual effects of hypnotics: an update. J Clin Psychiatry 1991;52:14-5.
97. Linnoila M, Erwin CW, Brendle A, Logue P. Effects of alcohol and flunitrazepam on mood and performance in healthy young men. J Clin Pharmacol 1981;21:430-5.
98. Seppälä T, Nuotto E, Dreyfus JF. Drug-alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. Pharmacology 1983;27:127-35.
99. Seppälä T, Dreyfus JF, Saario I, Nuotto E. Zopiclone and flunitrazepam in healthy subjects: hypnotic activity, residual effects on performance and combined effects with alcohol. Drugs Exp Clin Res 1982;8:35-47.
100. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13:1S-169S.
101. Willumeit HP, Ott H, Kuschel C. Effects of lormetazepam and other benzodiazepine receptor ligands on car driving-related skills. Hum Psychopharmacol 1991;6:209-18.
102. Volkerts ER, O'Hanlon JF. Residu effecten van voorgeschreven hypnotica op de actuele rijprestatie. Tijdschr Ther Geneesm Onderz 1985;10:919-28.
103. Volkerts ER, O'Hanlon JF. Hypnotics' residual effects on driving performance. In: O'Hanlon JF, JJ De Gier, eds. Drugs and driving. First International Symposium on Prescription Drugs and Driving Performance, Vinkeveen, The Netherlands, June 25-28, 1984. London, Philadelphia: Taylor and Francis, 1986:123-36.
104. Volkerts ER, O'Hanlon JF. Residu effecten op de actuele rijprestatie: zopiclone versus flunitrazepam en nitrazepam. Tydschr Ther Geneesm Onderz 1988;13:111-5.
105. O'Hanlon JF, Volkerts ER. Hypnotics and actual driving performance. Acta Psychiatr Scand 1986;332:95-104.
106. Schmidt U, Brendemühl D, Dellen R, Meurer Krüll BCh, Helm V. Verkehrsmedizinische aspekte einer schlafmitteltherapie unter besonderer berucksichtigüng von temazepam. Arzneimittelforschung 1985;35:1336-40.
107. Schmidt U, Brendemühl D, Rüther E. Aspects of driving after hypnotic therapy with particular reference to temazepam. Acta Psychiatr Scand 1986;332:112-8.
108. Vermeeren A, O'Hanlon JF, Declerck AC, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995;21:47-64.
109. Sicard BA, Trocherie S, Moreau J, Vieillefond H, Court LA. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med 1993;64:371-5.
110. Korttila K, Linnoila M. Skills related to driving after intravenous diazepam, flunitrazepam, or droperidol. Br J Anaesth 1974; 46:961-9.
111. Korttila K, Linnoila H. Amnesic action of and skills related to driving after intravenous flunitrazepam. Acta Anaesthesiol Scand 1976;20:160-8.
112. Laurell H, Törnros J. Interaction effects of hypnotics and alcohol on driving performance. J Traffic Med 1991;19:9-13.
113. Christophersen AS, Gjerde H, Bjørnebøe A, Sakshaug J, Mørland J. Screening for drug use among Norwegian drivers suspected of driving under influence of alcohol or drugs. Forensic Sci Int 1990;45:5-14.
114. Skurtveit S, Christophersen AS, Mørland J. Kjøring under påvirkning av benzodiazepiner: fylkesforskjeller i salget reflekteres blant bilførere mistenkt for kjøring i påvirket tilstand. Tidsskr Nor Laegeforen 1995;115:200-3.
115. Staub C, Lacalle H, Fryc O. Présence de psychotropes dans le sang de conducteurs responsables d'accidents de la route ayant consommé en même temps de l'alcool. Soz Präventivmed 1994; 39:14:3-9.
116. Clarke PRF, Bennett NR, Milne BR, Thornton JA. Gone but not forgotten: benzodiazepine-induced amnesia. Br J Anaesth 1980; 52:231.
117. Subhan Z. The effects of benzodiazepines on short-term memory and information processing. Psychopharmacology 1984;1:173-81.
118. Smirne S, Ferini-Strambi L, Pirola R, Tancredi O, Franceschi M, Pinto P, Bareggi SR. Effects of flunitrazepam on cognitive functions. Psychopharmacology (Berl) 1989;98:251-6.
119. Klein MJ, Patat A, Manuel C. Etude des effets sur la mémoire et les performances psychomotrices induits chez le sujet sain par 3 benzodiazépines hypnotiques (triazolam, flunitrazépam, loprazolam). Therapie 1986;41:299-304.
120. Sold M, Linder H, Weis KH. Zur Wirkung von fentanyl, diazepam und flunitrazepam auf die gedächtnisfunktion: eine pharmakopsychologische untersuchung. Anaesthesist 1983;32:519-24.
121. Fossen A, Godlibsen OB, Loyning Y, Dreyfus JF. Effects of hypnotics on memory. Pharmacology 1983;27:116-26.
122. Bixler EO, Scharf MB, Soldatos CR, Mitsky DJ, Kales A. Effects of hypnotic drugs on memory. Life Sci 1979;25:1379-88.
123. Ott H, Rohloff A, Aufdembrinke B, Fichte K. Anterograde and retrograde amnesia after lormetazepam and flunitrazepam. Psychopharmacol Ser 1988;6:180-93.
124. Jackson JL, Louwerens JW, Cnossen F, de Jong HT. Testing the effects of hypnotics on memory via the telephone: fact or fiction? Psychopharmacology 1993;111:127-33.
125. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology 1991;105:1-8.
126. Ghoneim MM. The reversal of benzodiazepine-induced amnesia by flumazenil: a review. Curr Ther Res 1992;52:757-67.
127. Gentil V, Gorenstein C, Camargo CHP, Singer JM. Effects of flunitrazepam on memory and their reversal by two antagonists. J Clin Psychopharmacol 1989;9:191-7.
128. Ingum J, Beylich KM, Mørland J. Amnesic effects and subjective ratings during repeated dosing of flunitrazepam to healthy volunteers. Eur J Clin Pharmacol 1993;45:235-40.
129. George KA, Dundee JW. Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man. Br J Clin Pharmacol 1977; 4:45-50.
130. McKay AC, Dundee JW. Effect of oral benzodiazepines on memory. Br J Anaesth 1980;52:1247-57.
131. Korttila K, Saarnivaara L, Tarkkanen J, Himberg JJ, Hytönen M. Comparison of diazepam and flunitrazepam for sedation during local anaesthesia for bronchoscopy. Br J Anaesth 1978;50: 281-7.
132. Kishi H, Koshino Y, Nakagawa H, Misaki K, Ota T, Kanda I, Okuda K, Ito T, Isaki K. The influence exerted on sleep EEG and memory by flunitrazepam or ethanol alone or in combination. In: Chase MH, Krueger J, O'Connor C, eds. Sleep Research 22:37. Los Angeles: University of California, Brain Information Service/Brain Research Institute, 1993.
133. Teo SH, Chee RT, Tan CT. Psychiatric complications of Rohypnol abuse. Singapore Med J 1979;20:270-3.
134. Dietch JT, Jennings RK Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988;49:184-8.
135. Foy A, O'Connell D, Henry D, Kelly J, Cocking S, Halliday J. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol 1995;50:M99-106.
136. Rameckers EM, Muileboom CA, van Santen GW. Onderzoek bij Amsterdamse apotheken naar afgelevcrde hoeveelheden tranquillizers en slaapmiddelen aan "gewone" patieënten en aan "druggebruikers." Ned Tijdschr Geneeskd 1987;131:1619-21.
137. IMS International, Inc., Plymouth Meeting, PA, 1996.
138. Rasker-Prins HA, Van Ham JM. Slaapnudde Iverslaving, alleen bij Amsterdamse, flunitrapam gebruikende druggebruikers? Pharmaceutisch Weekblad 1988;123:657-8.
139. Bergman U. Förbrukning av hypnotika, sedativa och ataraktika. Lakartidningen 1983;80:4651-2.
140. Lunde PKM, Bakasaas I, Halse M, Halvorsen IK, Stromnes B, Oydvin K. The methodology of drug utilization studies. In: Bergman U, Grimsson A, Wahba AHW, Westerholm B, eds. Studies in drug utilization, WHO Regional Publications, European Series 8. Copenhagen: World Health Organization, 1979:17-28.
141. Ekedahl A, Lidbeck J, Lithman T, Noroen D, Melander A. Benzodiazepine prescribing patterns in a high-prescribing Scandinavian community. Eur J Clin Pharmacol 1993;44:141-6.
142. Wessling A, Bergman U, Westerholm B. On the differences in psychotropic drug use between the three major urban areas in Sweden. Eur J Clin Pharmacol 1991;40:495-500.
143. Alran C, Damase-Michel C, Celotto N, Durand MC, Montastruc JL. Consumption of benzodiazepines in a French university hospital between 1980 and 1991. Fundam Clin Pharmacol 1993;7: 319-23.
144. Nappo S, Carlini EA. Preliminary finding: consumption of benzodiazepines in Brazil during the years 1988 and 1989. Drug Alcohol Depend 1993;33:11-7.
145. Ruiz I, Offermanns J, Fuentes P, Castillo M. Utilization of benzodiazepines in Chile during 1982-1986. Eur J Clin Pharmacol 1989;37:139-43.
146. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D. Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health 1993;17:345-9.
147. Jacobson GA, Friesen WT, Peterson GM, Rumble RH, Polack AE. Psychoactive drug prescribing in the Tasmanian community. Med J Aust 1992;157:20-4.
148. Urata J, Kamei Y, Okutsu T, Hasunuma M, Shirakawa S, Okawa M. The prescription of hypnotics in clinics of 6 national hospitals. Jpn J Natl Med Serv 1995;49:1068-72.
149. Berthoud S. Profil de prescriptions en Suisse romande et au Tessin: analyse de 2006 ordonnances médicales. Schweiz Med Wochenschr 1979;109:1194-200.
150. Ladewig D. Benzodiazepin - Verordnungen in apotheken der stadt Basel. Schweiz Apoth Ztg 1990;128:100-2.
151. Müller-Oerlinghausen B. Prescription and misuse of benzodiazepines in the Federal Republic of Germany. Pharmacopsychiatry 1986;19:8-13.
152. Veje JO, Andersen K, Gjesing S, Kielgast H. Neurose-og sovemiddelordination i Holbæk Kommune. Ugeskr Laeger 1989;151:2134-6.
153. Petit N, Delporte JP, Ansseau M, Albert A, Jeusette F. Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital. Pharm World Sci 1994;16:181-6.
154. Escrivá Torralva A, Molina Lázaro A, Vilanova Boltó M, Puigventós Latorre F, Longoni Merino M, Canellas Dois F. Evaluation de la utilizacion de benzodiazepinas en el hospital. Farmacia Clinica 1993;10:186,88,89,92-94,96,97.
155. Svestka J, Kamenická V, Lemanová H. Census of psychotropic drugs and other psychiatric care used in a psychiatric university department. Homeost Health Dis 1993;34:195-7.
156. Magni G, Schifano F, De Leo D, De Dominicis G, Renesto V, Vianello S. Evaluation of use patterns of psychotropic drugs in an Italian geriatric hospital. Neuropsychobiology 1985;13:38-43.
157. Mascarell E, Barba M, Aguas M, Soria X, Torres MD. Estudio de la utilización de psicofármacos en una unidad de convalecencia. Farm Clin 1995;12:353-8.
158. Janiri L, Di Giovanni A, Persico A, Zeppetelli E, Mannelli P, Antico L, Tempesta E. Consumo di benzodiazepine e rischio di dipendenza in pazienti geriatrici istituzionalizzati. Minerva Psichiatr 1991;32:151-63.
159. Nygaard HA, Rotevatn TS. Bruk av hypnotika hos eldre rehabiliteringspasienter. Tidsskr Nor Laegeforen 1993;113:3228-30.
160. Pakesch G, Katschnig H, Dittrich R, Loimer N, Rasinger E, Tutsch G. Prävalenz und soziodemographische korrelate des benzodiazepingebrauchs in einer großstadtbevölkerung. Nervenarzt 1993;64:312-7.
161. Barnas C, Fleischhacker WW, Whitworth AB, Schett P, Stuppäck C, Hinterhuber H. Characteristics of benzodiazepine long-term users: investigation of benzodiazepine consumers among pharmacy customers. Psychopharmacology 1991;103:233-9.
162. Rozemberg B. O consumo de calmantes e o "problema de nervos" entre lavradores. Rev Saúde Pública 1994;28:300-8.
163. Geiselmann B, Linden M. Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry 1991;24:55-61.
164. Vissers FHJA, Knottnerus JA, Van der Grinten RF, Van der Horst FGEM. Langdurig gebruik van slaap - en kalmeringsmiddelen in een huisartspraktijk. Huisarts Wet 1993;36:405-8.
165. Verhaeghe W, Mets T, Corne L. Benzodiazepine use among elderly patients presenting at the emergency room. Arch Gerontol Geriatr 1996;22:55-62.
166. Ladewig D. Abuse of benzodiazepines in western European society - incidence and prevalence, motives, drug acquisition. Pharmacopsychiatria 1983;16:103-6.
167. Ladewig D, Grossbacher H. Benzodiazepine abuse in patients of doctors in domiciliary practice in the Basle area. Pharmacopsychiatry 1988;21:104-8.
168. Kielholz P, Ladewig D. Probleme des medikamentenmiss-brauches. Schweiz Apoth Ztg 1980;118:620-2.
169. Ladewig D, Meng H. Medikamenten- und drogenabhängigkeit bei patienten psychiatrischer kliniken. Schweiz Rundschau Med Praxis 1983;72:982-6.
170. Ladewig D, Schroeter U. Drug dependence in patients in psychiatric hospitals in Switzerland: a survey conducted in nine psychiatric hospitals from 1983-1986. Pharmacopsychiatry 1990; 23:182-6.
171. Ladewig D, Schroeter U. Mißbrauch und abhängigkeit von medikamenten und drogen. Schweiz Apoth Ztg 1988;126:552-8.
172. Priebe S, Liesenfeld O, Müller-Oerlinghausen B. Does routine screening for benzodiazepines help to diagnose dependence in psychiatric inpatients? Acta Psychiatr Scand 1989;80:514-7.
173. Keup W. Mißbrauch und abhängigkeit von sedativa und hypnotika. Internist 1986;27:746-56.
174. Poser W, Piesiur-Strehlow B. Mißbrauch von Benzodiazepinen aus psychiatrischer sicht. Schweiz Apoth Ztg 1985;123:778-83.
175. Perera KMH, Tulley M, Jenner FA. The use of benzodiazepines among drug addicts. Br J Addict 1987;82:511-6.
176. San L, Tato J, Torrens M, Castillo C, Farré M, Camí J. Flunitrazepam consumption among heroin addicts admitted for inpatient detoxification. Drug Alcohol Depend 1993;32:281-6.
177. Cervera-Martinez G, Rojo Moreno L, Bolinches Claramonte F, Valderrama Zurian JC, Martinez Raga J, Dominguez Carabantes A. La conducta adictiva: el consumo y la dependencia de benzodiacepinas en dependientes a opiáceos. An Psiquiatr 1992; 8:22-6.
178. Korf DJ, Hoogenhout HPH. Slaap- en kalmeringsmiddelen op de Amsterdamse drugsmarkt. Pharm Weekbl 1989;124:95-100.
179. Leone L, Moretti V. Monitoring of licit psychoactive drug abuse trends in Italy. Br J Clin Pharmacol 1986;21:119P-120P.
180. Barattini M, Fantozzi R, Masini E, Mannaioni PF. L'abuso di farmaci leciti nei tossicodipendenti da eroina. Clin Ter 1987;120: 183-98.
181. Eugene D, Deschamps D, Castot A, Menerath C, Lagier G, Dally S. Dependances medicamenteuses: de nouveaux moyens. Therapie 1994;49:64.
182. Navaratnam V, Foong K. Natural history of heroin addiction and adjunctive drug use. Research Report 16, Centre for Drug Research, Universiti Sains Malaysia Pulau Pinang, Malaysia, 1988.
183. Navaratnam V, Foong K. Opiate dependence - the role of benzodiazepines. Curr Med Res Opin 1990;11:620-30.
184. Hartog J, Tusel DJ. Valium use and abuse by methadone maintenance clients. Int J Addict 1987;22:1147-54.
185. Gossop M, Battersby M, Strang J. Self-detoxification by opiate addicts: a preliminary investigation. Br J Psychiatry 1991;159: 208-12.
186. Steentoft A, Worm K, Pedersen CB, Sprehn M, Mogensen T, Sorensen MB, Nielsen E. Drugs in blood samples from unconscious drug addicts after the intake of an overdose. Int J Legal Med 1996;108:248-51.
187. Calhoun SR, Wesson DR, Galloway GP, Smith DE. Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and South Texas. J Psychoactive Drugs 1996;28:1-7.
188. Wesson DR, Calhoun S, Smith DE. "Roache" abuse along the Texas-Mexico Border. In: Abstracts, College on Problems of Drug Dependence, San Juan, Puerto Rico, June, 1996, p. 149.
189. Maddaleno M, Florenzano R, Santa Cruz X, Vidai R. Consumo de flunitrazepan via nasal en adolescents marginales de Santiago de Chile. Rev Méd Chil 1988;116:691-4.
190. Bergman U, Dahl-Puustinen ML. Use of prescription forgeries in a drug abuse surveillance network. Eur J Clin Pharmacol 1989; 36:621-4.
191. Lemozit JP, Vabre F, Lapeyre-Mestre M, Damase-Michel C, Montastruc JL. Pourriez-vous me donner ce médicament sans ordonnance? Therapie 1995;50:464-6.
192. Strang J, Griffiths P, Abbey J, Gossop M. Survey of use of injected benzodiazepines among drug users in Britain. BMJ 1994; 308:1082.
193. Velvart J. Mehr selbstmorde als verkehrstote in der Schweiz. Euromed 1978;18:822,825.
194. Lorent JP. Intoxications médicamenteuses en Suisse en 1980. Schweiz Apoth Ztg 1981;119:284-9.
195. Redlich M, Hofer P, Dubach UC, Klüppelberg J. Absichtliche arzneimittelintoxikationen aus epidemiologischer, notfallmedizinischer und therapeutischer sicht. Schweiz Rundsch Med Prax 1986;75:1412-5.
196. Michel K, Arestegui G, Spuhler T. Suicide with psychotropic drugs in Switzerland. Pharmacopsychiatry 1994;27:114-8.
197. Michel K, Waeber V, Valach L, Arestegui G, Spuhler T. A comparison of the drugs taken in fatal and nonfatal self-poisoning. Acta Psychiatr Scand 1994;90:184-9.
198. Kessler R, Ryser DH. Der drogenpatient als notfall. Schweiz Rundsch Med Prax 1991;80:31-5.
199. Ray JE, Reilly DK, Day RO. Drugs involved in self-poisoning: verification by toxicological analysis. Med J Aust 1986;144:455-7.
200. Chen JS, Chang KJ, Charng RC, Lai SJ, Binder SR, Essien H. The development of a broad-spectrum toxicology screening program in Taiwan. Clin Toxicol 1995;33:581-9.
201. Pycha R, Barnas C, Miller C, Stuppäck C, Fleischhacker WW. Flunitrazepam for the I.V. treatment of alcohol-withdrawal-delirium (AWD). Biol Psychiatry 1991;29:511S.
202. de Montblanc J, Benkel J, Mathieu G, Abbeys JM. Diagnostic précoce d'une intoxication aigǔé dans un service d'urgence. Med Urgence 1994;4:163-6.
203. von Clarman M. Akute Vergiftungen Durch Schlafmittel. Internist (Berl) 1984;25:559-68.
204. De Maio D, Carnevali R, Sironi PG, Scieghi G, Rossati M, Finazzi M, Riva C, Galletta J. Analisi clinico-statistica sull' "overdose" acuto autolesivo da benzodiazepine. Riv Farmacol Ter 1980;11:33-4.
205. Haberhauer G, Fries W, Leitner A. Beitrag zur epidemiologie medikamentöser suizidversuche in Wien. Wien Klin Wochenschr 1994;106:69-74.
206. Pommereau X, Favarel-Garrigues JC. Tentatives de suicide par intoxication volontaire aiguë: le risque de récidive est majeur dans les six mois suivant une première tentative. Rev Prat Med Gen 1990;81:31-4.
207. Alsen M, Ekedahl A, Loewenhielm P, Nimeus A, Regnell G. Traeskman-Bendz L. Medicine self-poisoning and the sources of the drugs in Lund, Sweden. Acta Psychiatr Scand 1994;89:255-61.
208. Misfeldt J, Blichfeldt J. Forgiftningsdødsfald i vejle amt 1980-1985. Ugeskr Lëger 1986;148:243:3-7.
209. Coleridge J, Cameron PA, Drummer OH, McNeil JJ. Survey of drug-related deaths in Victoria. Med J Aust 1992;157:459-62.
210. Ruch R, Jaber B, Hilton S, Goertz E. Oral benzodiazepines -safety in overdose: 20 years of experience. Neuropsychopharmacology 1994;10:227S.
211. Jäger U, Hruby K, Haubenstock A, Fasching I. Vergleichende klinische toxikologie von 5 benzodiazepinederivaten. Nervenarzt 1984;55:150-3.
212. Pulce C, Mollon D, Pham E, Frantz P, Descotes J. Acute poisonings with ethyl loflazepate, flunitrazepam, prazepam and triazolam in children. Vet Hum Toxicol 1992;34:141-3.
213. Langendijk PNJ, Van Loenen AC, Van Heyst ANP. Overdosis met flunitrazepam en enkele andere benzodiazepmes: ervanngen van het Nationaal Vergiftigingeninformatiecentrum. Pharm Weekbl 1986;121:1212-8.
214. Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ 1995;310:219-21.
215. Höjer J, Baehrendtz S, Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 1989;226:117-22.
216. Serfaty M Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 1993;163: 386-93.
217. Ericsson HR, Holmgren P, Jakobsson SW, LaFolie P, de Rees B. Bensodiazepinfynd i Obduktionsmaterial: studie påvisar samverkande faktorer vid dodsfall. Lakartidningen 1993;90:3954-7.
218. Deleted in proofs.
219. Gossweiler B. Vergiftungen mit Rohypnol. Schweiz Apotn Ztg 1984;122:889-93,898.
220. Greenblatt DJ, Allen MD, Noel BJ, Shader RI. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther 1977;21: 497-514.
221. Iarlori R. Intoxicacion por flunitrazepam. Rev Hosp Ninos 1977; 19:84.
222. Roald OK, Dahl V. Flunitrazepam intoxication in a child successfully treated with the benzodiazepine antagonist flumazenil. Crit Care Med 1989;17:1355-6.
223. Heyndrickx B. Fatal intoxication due to flunitrazepam. J Anal Toxicol 1987;11:278.
224. Horwitz N. Akut sovemiddelforgiftning med flunitrazepam (Rohypnol) hos en ëldre patient. Ugeskr Laeger 1980;142:2429-30.
225. Nicolai P, Di Carlo M, Alfani F, Cerbo R, Smeriglio M, Borgo S, Cipriani E, Tarquini S, Malizia E. La nostra eperienza sull'intossicazione acute da flunitrazepam. Riv Tossicol Sper Clin 1982;12:47-51.
226. Drummer OH, Syrjanen ML, Cordner SM. Deaths involving the benzodiazepine flunitrazepam. Am J Forensic Med Pathol 1993; 14:238-43.
227. Mignée C, Gamier R, Conso F, Efthymiuo E, Fournier E. Intoxication aiguë par le flunitrazépam. Therapie 1980;35:581-9.
228. Meier PJ, Wyss PA, Radovanovic DI. Differential acute overdose toxicity of various benzodiazepine derivatives. Vet Hum Toxicol 1993;35:338.
229. Magura S, Goldsmith D, Casriel C, Goldstein PJ, Lipton DS. The validity of methadone clients' self-reported drug use. Int J Addict 1987;22:727-50.
230. World Health Organization. Critical review of flunitrazepam, PSA/ECDD29/3, Annex 4. Geneva: World Health Organization, 1994.
231. Drug Enforcement Administration. Flunitrazepam (Rohypnol): "roofies" DEA Publications, http://www.usdoj.gov/dea/pubs/rohypnol/rohypnol.htm, Washington, DC: US Drug Enforcement Administration, 1996.
232. Reynolds JEF, ed. Martindale: the extra pharmacopoeia, 31st ed., London: Royal Pharmaceutical Society, 1996.